Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 4, 2021

View Archived Issues

Novel urotensin II receptor antagonists show efficacy in a mouse pressor response model

Novel thrombosis mouse models using Jak2 platelet conditional knockout

ShanghaiTech University patents ALK-targeting PROTACs

Medshine Discovery discloses new FGFR/VEGFR2 dual inhibitors

GlaxoSmithKline plc identifies new mTOR inhibitors

University of Alberta discovers ERCC1 inhibitors

U.S. researchers divulge new antibodies against C. difficile

B cell transcription factor helps gut regenerate

Axsome begins second pivotal study of AXS-05 in Alzheimer's disease agitation

Orca-T precision-engineered Treg grafts improve incidence of acute and chronic GvHD

AXS-07 provides durable migraine pain relief in phase III MOVEMENT trial

Patient dosing underway in phase Ib/II study of NP-137 for endometrial or cervix carcinoma

RedHill reports topline phase II data on opaganib in patients hospitalized with COVID-19 pneumonia

Investigators present new CRLF2-targeting antibody for Ph-like pediatric ALL

T-cell epitope-based COVID-19 vaccine EPV-CoV19 advances towards clinic

New humanized murine model of myelofibrosis shows therapeutic vulnerability

FDA clears IND for PBGM-01 for infantile GM1 gangliosidosis

HY-1702 found to be protective in LPS-induced respiratory distress syndrome in mice

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.